// App-Quantinova.ai

5935 : Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome

Researchers

Presenter

  • R.J. Chilton

Principal Investigators

  • L. Gullestad

  • D. Fitchett

  • S.E. Inzucchi

  • M. Mattheus

  • H.J. Woerle

  • O.E. Johansen

Medical Centers

  • University of Texas Health Science Center, Dept of Medicine, San Antonio, United States of America

  • Oslo University Hospital, Gastroenterology, Oslo, Norway

  • St Michaels Hospital, Respiratory Medicine, Toronto, Canada

  • Yale University, Section of Endocrinology, New Haven, United States of America

  • Boehringer Ingelheim, Biometrics and datamanagement, Ingelheim, Germany

  • Boehringer Ingelheim, TA Cardiometabolism, Ingelheim, Germany

  • Boehringer Ingelheim Norway KS, TA Cardiometabolism, Asker, Norway

Locations

  • Norway

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Sex hormone binding globulin

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved